CYP51: A Potential Target

Aarti Singh, Swapnil S, Kanika V and Sarvesh P
Additional contact information
Sarvesh P: Department of Pharmacy, Banasthali University, India

Novel Approaches in Drug Designing & Development, 2017, vol. 2, issue 1, 6-9

Abstract: CYP51 has been emerged as a potential therapeutic target in the management of microbial infections. In recent years, inhibitions of CYP51 enzyme in treatment of microbial diseases have successfully declined the rate of mortality and morbidity especially in immune-compromised patients. CYP51 has now been considered as established therapeutic target for the treatment of fungal infections, leishmanial disease and many more. There is still a lot to unfold within the structure of CYP51 which could help the researchers to make it a more versatile target in the management of complex diseases.

Keywords: juniper publishers; drug designing pdf; drug designing articles; drug designing abstract; drug designing journal; modern approaches in drug designing journal; drug designing & intellectual properties international journal; peer reviewed open access journals; high impact journals; juniper publishers review (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/napdd/pdf/NAPDD.MS.ID.555577.pdf (application/pdf)
https://juniperpublishers.com/napdd/NAPDD.MS.ID.555577.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jnapdd:v:2:y:2017:i:1:p:6-9

DOI: 10.19080/NAPDD.2017.02.555577

Access Statistics for this article

Novel Approaches in Drug Designing & Development is currently edited by Sophia Mathis

More articles in Novel Approaches in Drug Designing & Development from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().